Navigation Links
Stem Cell Sciences Licenses Stem Cell Technology to Leading Provider of Genetically Modified Models for Pharmaceutical Research
Date:11/11/2008

CAMBRIDGE, England, November 11 /PRNewswire-FirstCall/ --

- ("Stem Cell Sciences", "SCS", "the Company")

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, announces that it has licensed IRES technology to a leading provider of genetically modified rat and mouse models for medical and pharmaceutical research. Under the terms of the multi-year agreement, which is non-exclusive and retroactive, the undisclosed partner will gain access to the IRES technology for use in its own research and development activities. Under the terms of the licence, SCS will receive US$750,000 over six years plus royalties.

SCS' IRES (Internal Ribosome Entry Site) technology enables researchers to monitor the activity of a particular gene of interest in living cells or tissues without blocking the normal function of the gene. In particular, IRES is important for evaluating the success of gene knock-outs or knock-ins in stem cells, which is crucial for the successful creation of transgenic mouse and rat disease models.

Dr Alastair Riddell, CEO of SCS, said "A key element of our commercial strategy is to realise both immediate and longer-term value from our extensive IP portfolio in the stem cell field through licence agreements such as this. We are therefore very pleased to have signed this agreement with one of the leading providers of transgenic animal models to the pharmaceutical research industry. We are continuing discussions with other companies, which may benefit from the use of SCS technology in conjunction with their own, and are optimistic of signing further agreements in the coming months."

About Stem Cell Sciences plc

Stem Cell Sciences (SCS) is an international research and development company focusing on the commercial application of stem cell biology technologies for drug discovery and regenerative medicine research. Stem Cell Sciences is now focussing on building revenues through the sale of products, collaborative research and licensing deals with international biotechnology and pharmaceutical companies.

Stem Cell Sciences has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. The Company has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify adult and embryonic stem cells. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny (specialised tissue cell types) for use in genetic, pharmacological and toxicological screens. Moreover, these technologies may be able to provide pure populations of appropriate cell types for transplantation therapies in the future.

The Company has its main research base and headquarters in Cambridge, UK with a second research base in Monash near Melbourne, Australia and a business development office in San Francisco, USA.

For further information on the company please visit: http://www.stemcellsciences.com.

For further information, please contact:

Stem Cell Sciences plc (United Kingdom)

Alastair Riddell, CEO

Tim Allsopp, Chief Scientific Officer

+44(0)1223-499160

Stem Cell Sciences pty ltd (Australia)

Paul Bello, Operations Manager

+61(0)400-500-495

Citigate Dewe Rogerson (UK)

Mark Swallow / Emma Palmer Foster / Amber Bielecka

+44(0)20-7638-9571

Talk Biotech (Australia)

Fay Weston, Director

+61(0)422-206-036

Daniel Stewart & Company (NOMAD to SCS, UK)

Simon Leathers / Simon Starr

+44(0)207-776-6566


'/>"/>
SOURCE Stem Cell Sciences plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
5. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
10. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
11. The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Sinovac Biotech Ltd. ("Sinovac" or the ... biopharmaceutical products in China , today ... directors received on February 4, 2016 a preliminary non-binding ... comprised of PKU V-Ming ( Shanghai ) ... Qianhai Development ( Shenzhen ) Fund Management ...
(Date:2/3/2016)... Feb. 3, 2016   ViaCyte, Inc ., ... first pluripotent stem cell-derived islet replacement therapy for ... development, today announced that ViaCyte and Janssen Biotech, ... Johnson & Johnson, have agreed to consolidate the ... The agreement provides ViaCyte with an exclusive license ...
(Date:2/3/2016)... 3, 2016 Harvard Apparatus Regenerative Technology, ... developing bioengineered organ implants for life-threatening conditions of ... CEO Jim McGorry , will present at ... on Tuesday, February 9, 2016 at 8:00 am ... . HART,s presentation will be webcast live and ...
(Date:2/3/2016)... ... 03, 2016 , ... StarNet Communications Corp, ( http://www.starnet.com/ ) ... addition of a powerful “Session Preview” feature to its FastX remote Linux visualization ... remote Linux desktop or other applications (sessions) they have running on a remote ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
(Date:1/22/2016)... January 22, 2016 ... addition of the  "Global Behavioral Biometric ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ... Behavioral Biometric Market 2016-2020"  report to ... and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ...
(Date:1/21/2016)... 2016 --> ... research report "Emotion Detection and Recognition Market by Technology (Bio-Sensors, ... Expression, Voice Recognition and Others), Services, Application Areas, ... 2020", published by MarketsandMarkets, the global Emotion Detection ... 22.65 Billion by 2020, at a CAGR of ...
Breaking Biology News(10 mins):